Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors
Authors:
- Koshiro FukudaKFKoshiro Fukuda
- Hiroki OsumiHOHiroki Osumi
- Koichiro YoshinoKYKoichiro Yoshino
- Izuma NakayamaIzuma Nakayama
- Shota FukuokaSFShota Fukuoka
- Mariko OguraMOMariko Ogura
- Takeru WakatsukiTWTakeru Wakatsuki
- Akira OokiAOAkira Ooki
- Daisuke TakahariDTDaisuke Takahari
- Keisho ChinKCKeisho Chin
- Kensei YamaguchiKYKensei Yamaguchi
- Eiji ShinozakiESEiji Shinozaki
Open Access
- 6 July 2023
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 23 (1) , 1-10
Abstract
Background: Few studies have focused on the impact of single-organ pulmonary metastases on progression-free survival and overall survival in patients with metastatic colorectal cancer. Recognizing differences in prognosis and chemotherapeutic efficacy based on metastasized organs may help in optimizing treatment strategies. The exploratory study was conducted to evaluate the comparative clinical outcomes and prognoses of patients with metastatic colorectal cancer presenting with single-organ pulmonary metastases and treated with folinic acid, 5-fluorouracil, irinotecan, and vascular endothelial growth factor inhibitors as second-line chemotherapy. Methods: This retrospective study included 289 patients with metastatic colorectal cancer treated with second-line folinic acid, 5-fluorouracil, irinotecan, and vascular endothelial growth factor inhibitors. The response rate, disease control rate, progression-free survival, and overall survival were assessed in the participants. Results: Among the 289 patients enrolled, 26 (9.0%) had single-organ pulmonary metastasis with left-sided primary locations, lower levels of tumor markers at the initiation point of chemotherapy, a significantly higher disease control rate (96.2% vs. 76.7%, P = .02), and a longer progression-free survival (median 29.6 months vs. 6.1 months, P < .001) and overall survival (median 41.1 months vs. 18.7 months, P < .001) than patients with other forms of metastatic colorectal cancer. Multivariate analysis showed that single-organ pulmonary metastasis was an independent predictor of longer progression-free survival (hazard ratio 0.35, P = .00075) and overall survival (hazard ratio 0.2, P = .006). Conclusion: Single-organ pulmonary metastasis was a strong predictor of progression-free survival and overall survival in patients with metastatic colorectal cancer treated with folinic acid, 5-fluorouracil, irinotecan, and vascular endothelial growth factor inhibitors as second-line chemotherapy; this provides preliminary evidence for medical guidelines and clinical decision-making on novel therapeutic strategies for these patients.Keywords
All Related Versions
This publication has 41 references indexed in Scilit:
- Comparing Time to Disease Progression of Irinotecan and Oxaliplatin-based Chemotherapies in Colorectal Cancer Patients With Liver Only MetastasisAmerican Journal of Clinical Oncology, 2013
- Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasisCancer Chemotherapy and Pharmacology, 2013
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Survival Differences in Patients With Metastatic Colorectal Cancer and With Single Site Metastatic Disease at Initial Presentation: Results From South Australian Clinical Registry for Advanced Colorectal CancerClinical Colorectal Cancer, 2012
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based RegimenJournal of Clinical Oncology, 2012
- Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based studyGut, 2010
- Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: A multicenter studySurgery, 2007
- Characteristic Differences between Patients Who Have Undergone Surgical Treatment for Lung Metastasis or Hepatic Metastasis From Colorectal CancerThe Thoracic and Cardiovascular Surgeon, 2005
- Benefits of surgery for patients with pulmonary metastases from colorectal carcinomaThe Annals of Thoracic Surgery, 2004
- Lung recurrence after curative surgery for colorectal cancerDiseases of the Colon & Rectum, 1987